Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Completion of Phase I Clinical Study of CardiolRx
Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Completion of Phase I Clinical Study of CardiolRx Oakville, Ontario--(Newsfile Corp. - December 22, 2020) - Cardiol Therapeutics Inc. ( Cardiol" or the " Company"), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, is pleased to announce completion of the Company's Health Canada approved Phase I clinical study of CardiolRx. CardiolRx is an ultra-pure, extra strength cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP, and THC-free ( Car...
Source: finanznachrichten.de